Start the conversation
Shares of Trius Therapeutics Inc. (Nasdaq: TSRX) jumped more than 8.2% yesterday after the "Super Bug" drug researcher received a highly favorable ruling about its core technology from the U.S. Patent and Trademark Office (USPTO).
Resident tech expert Michael Robinson recommended Trius to Private Briefing subscribers back on March 26, telling us the company's research into such life-threatening infections as methicillin-resistant Staphylococcus aureus (MRSA) made this a high-profit-potential stock.
Many Big Pharma firms have killed off their antibiotic-drug research programs (antibiotics sell for hundreds of dollars per dose, instead of the tens of thousands that treatments for cancer and other maladies command). And that's created a huge opportunity for the San Diego-based Trius, Michael says.
This is premium content for Private Briefing subscribers only.